Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dirksen Bussiere

Dirksen Bussiere

Novartis, USA

Title: TBA

Biography

Biography: Dirksen Bussiere

Abstract

Several biological functions, particularly chromosome segregation, require the generation of motile force.  The generation of this force relies heavily on a class of proteins known as motor proteins.  Motor proteins such as Kinesin Spindle Protein (KSP), also known as Eg5, utilize the energy derived from ATP hydrolysis to generate motile force.  High-throughput screening of Eg5 identified several hits which were non-competitive with ATP with micromolar IC50’s capable of inhibiting the motor protein.  Using structure-based drug design, these hits were progressed to NVP-BQS481, a clinical candidate with an IC50 of 700 picomolar.  The talk will present the design concepts and optimization techniques used to advance the series to the pre-clinical stage.

References:

  1. Barsanti, PA, Wang, W, Duhl, D, Brameier, N, Martin, E, Bussiere, D, Walter AO (2010)  The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5. Bioorg Med Chem Lett 20(1): 157-160.
  2. Murray, JM, Bussiere DE (2009) Targeting the purinome.  Methods Mol Biol 575: 47-92.
  3. Mayer, TU, Kapoor, TM, Haggarty, SJ, King RW, Schreiber, SL, Mitchison, TJ  (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in phenotype-based screen.  Science 286: 971-974.
  4. Duhl, DM, Renhowe PA (2005) Inhibitors of kinesin motor proteins—research and clinical progress.  Curr Opin Drug Discov Devel 8(4): 431-436.
  5. Bergnes, G, Brejc, K, Belmont, L (2005) Mitotic kinesins:  prospects for antimitotic drug discovery.  Curr Top Med Chem 5(2): 127-145.